Navigation Links
Evotec Expands Collaboration With InterMune
Date:3/6/2008

e, but are not limited to, statements about the anticipated benefits of Evotec's products and services, the payments that Evotec may receive under its collaboration agreement with Intermune, the anticipated timing and results of Evotec's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information as a result of risks and uncertainties. These include risks and uncertainties relating to: Evotec's ability to complete the merger because conditions to the closing of the merger may not be satisfied; the failure to successfully integrate the businesses of Evotec and Renovis; unexpected costs or liabilities resulting from the merger; the risk that synergies from the merger may not be fully realized or may take longer to realize than expected; disruption from the merger making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; development, use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations.

The risks included above are not exhaustive. The Registration Statement on Form F-4 filed by Evotec with the Securities and Exchange Commission contains additional factors that could impact the combined company's businesses and financial performance. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Evotec Starts Phase II in Smoking Cessation with EVT 302
11. ATS Medical Expands Open Pivot Heart Valve Offerings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... NY (PRWEB) March 02, 2015 In ... Services industry has experienced robust growth. The industry, ... products, industrial materials, energy resources and other goods, has ... rising government regulation. As a result, IBISWorld forecasts that ... 2.8% to reach $946.8 million over the five-year period, ...
(Date:3/2/2015)... , March 2, 2015 Analyzing ... experts have identified a new syndrome, shedding light ... research also provides important information to help caregivers ... eventually treating it. "This syndrome illuminates ... sort of master switch that controls many other ...
(Date:3/2/2015)... NEW YORK and VANCOUVER, British ... Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a ... of cannabinoid based therapies, today announced that ... a company overview during a live webcast at ... TIME:  1:15pm ET LINK:   http://VirtualInvestorConferences.com > click ...
(Date:3/2/2015)... CORAL SPRINGS, Florida , March 2, 2015 ... products, science-based pharmaceuticals and healthy whole food nutrition ... for treatments of lifestyle related disorders such as ... illnesses and health concerns.  Nutraceutical and Biotech Companies ... RIBT ), Amira Nature Foods Ltd. (NYSE: ...
Breaking Biology Technology:Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4InMed Pharmaceuticals to Present Investor Webcast March 5 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7
... YORK , June 11 The Champalimaud Foundation, ... that Dr. J. Anthony Movshon , Director of ... William T. Newsome , Investigator at The Howard Hughes ... , are the recipients of its 2010 Vision Award.  The ...
... Genomic Health, Inc. (Nasdaq: GHDX ) today announced the ... of Clinical Oncology (ASCO) Annual Meeting, including an evaluation of ... cancer, suggesting a potential role for the Onco typ e ... pending further study. The company also announced the first presentation ...
... , June 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... will host a conference call and webcast on Monday, June 7th, 2010 ... discuss the Phase I/II head and neck cancer data being presented that day ... , , ...
Cached Biology Technology:Prestigious International Champalimaud Vision Award to US Scientists 2Prestigious International Champalimaud Vision Award to US Scientists 3Prestigious International Champalimaud Vision Award to US Scientists 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 9Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting 3
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... ISRAEL, August 9, 2010 Ben-Gurion University of the Negev ... Samuel and Paula Elkeles Prize for Outstanding Scientist in the ... the Shraga Segal Department of Microbiology and Immunology and vice ... of Health Sciences. He is also the Irving Sklar ...
... is available in German . , Spectroscopic techniques ... look inside materials. They exploit the interaction of light waves ... spectroscopy, researchers from Helmholtz-Zentrum Berlin fr Materialien und Energie (HZB) ... solvent so-called electron transfer. They can even make assertions ...
... of Case Western Reserve University School of Medicine, has ... Pioneer Award. One of 17 awardees to ... genetic effects, where the biological features and disease risk ... much on the genetics of ancestral generations as on ...
Cached Biology News:Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research 2Help from the dark side 2Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: